Discovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1).
Rajapakse, H.A., Nantermet, P.G., Selnick, H.G., Munshi, S., McGaughey, G.B., Lindsley, S.R., Young, M.B., Lai, M.T., Espeseth, A.S., Shi, X.P., Colussi, D., Pietrak, B., Crouthamel, M.C., Tugusheva, K., Huang, Q., Xu, M., Simon, A.J., Kuo, L., Hazuda, D.J., Graham, S., Vacca, J.P.(2006) J Med Chem 49: 7270-7273
- PubMed: 17149856 
- DOI: https://doi.org/10.1021/jm061046r
- Primary Citation of Related Structures:  
2IRZ, 2IS0 - PubMed Abstract: 
We describe the discovery and optimization of tertiary carbinamine derived inhibitors of the enzyme beta-secretase (BACE-1). These novel non-transition-state-derived ligands incorporate a single primary amine to interact with the catalytic aspartates of the target enzyme. Optimization of this series provided inhibitors with intrinsic and functional potency comparable to evolved transition state isostere derived inhibitors of BACE-1.
Organizational Affiliation: 
Department of Medicinal Chemistry, Merck Research Laboratories, P.O. Box 4, West Point, Pennsylvania 19486, USA. hemaka_rajapakse@merck.com